Navigation Links
Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants

ANN ARBOR, Mich., April 28 /PRNewswire/ -- Terumo Heart, Inc. announced a presentation at the recent ISHLT meeting in Boston. The presentation entitled "Long Term Circulatory Support with the DuraHeart(TM) Mag-Lev Centrifugal LVAS for Advanced Heart Failure Patients Eligible for Transplantation: European Experience" was delivered by Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc.

(Photo: )

(Logo: )

(Logo: )

The presentation summarized results of 55 patients (33 in the CE-mark trial and 22 after market launch) who were implanted with the DuraHeart(TM) (LVAS) Left Ventricular Assist System between January 2004 and March 2008. The average duration of support was 214 +/- 226 days with a cumulative duration of 32 years. The Kaplan-Meier (K-M) survival was 82% at 6 months and 77% at 1 year. Eighteen patients (33%) were transplanted at 181 +/- 135 days. Thirteen patients (24%) were supported > 1 year with the mean support duration of 568 +/- 183 days and 2 were supported > 2 years. Twenty-seven patients (49%) remain on support for 274 +/- 276 (17-1,001) days.

K-M survival at 1 year in the CE-mark trial was 100% in patients < 50 years, 94% in those < 60 years, 80% in those < 65 years, and 67% in those greater than or equal to 65 years. Stroke free survival at 1 and 2 years in the CE-mark trial (33 patients) was 94% for the last 22 patients after implementing a less intensive anticoagulation/anti-platelet regimen. There was no pump mechanical failure, pump thrombosis, or hemolysis throughout the support duration. Dr. Chisato Nojiri commented; "We are very pleased with the long term results of the device and recently reached a major milestone with a patient reaching 1,000 days of support. This patient will reach 3 years on the device on July 4th 2008."

The presentation concluded that the DuraHeart LVAS provides safe and reliable long-term circulatory support with improved survival. High device reliability and a low stroke rate despite less intensive anticoagulation offer easier out-of-hospital management.

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only CE marked implantable LVAS combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart LVAS is not available for sale in the United States. As reported previously, Terumo Heart has received conditional approval from the FDA to commence a multicenter pivotal trial in the United States and plans to conduct the first implants at its principal investigational sites in the near future.

Terumo Heart, Inc. is a US subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products.

SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
2. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
3. Many Heart Attack Patients Dont Get Best Emergency Treatment
4. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
5. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
6. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
(Date:10/13/2015)... Ga. , Oct. 13, 2015  EndoChoice Holdings, ... its third quarter 2015 financial results on Thursday, November ... . --> . ... on Thursday, November 5, 2015 at 9:00 a.m. ET ... 328-5344 for domestic callers and (412) 317-5469 for international ...
(Date:10/13/2015)... --> --> ... from the Asthma and COPD Therapies market? Which areas are ... brand new report shows you potential revenues to 2025, assessing ... provides 260 tables, charts, and graphs. Discover the most lucrative ... new study lets you assess forecasted sales at overall world ...
(Date:10/13/2015)... 13, 2015  XiMo AG ( Lucerne ... Inc. ( Milpitas, California ) announced today ... chemistry. The importance of metathesis chemistry was highlighted by ... of this application. This industrially-relevant application has been utilized ... pharmaceuticals, specialty chemicals, and polymers. Georg Fráter ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Scientists in ... tissue biopsy in 18 patients with or without mesothelioma. Surviving Mesothelioma has just posted ... , The doctors from PhenoPath Laboratories in Seattle and the University of British Columbia ...
(Date:10/13/2015)... ... , ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, ... for more than 5 years. A leading cause of emergency room visits, school ... is not timely. , Sedation dentistry provides an anxiety-free dental experience ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, an ... newest professional to introduce the latest development, ThermiVa® temperature controlled radiofrequency to the ... professional in Obstetrics and Gynecology and a pioneer in the field of laparoscopy. ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):